Composition for anti-inflammation containing 5-adamantan-1-yl-N-(2,4-dihydroxy-benzyl)-2,4-dimethoxy-benzamide

Abstract

5-Adamantan-1-yl-N-(2,4-dihydroxybenzyl)-2,4-dimethoxybenzamide disclosed in the present disclosure lacks toxicity and can exhibit superior anti-inflammatory effect. It exhibits superior anti-inflammatory effect, for example, by inhibiting the production of one or more of NO and PGE2, by inhibiting the activity of one or more of the transcription factors NF-κB and AP-1 or by inhibiting proinflammatory cytokines such as IL-1β.

What is claimed is: 
     
       1. A method for inhibiting one or more of the following activities in a subject suffering from inflammation:
 (i) the production of one or more of NO and PGE2; 
 (ii) the expression of one or more of iNOS and COX-2; 
 (iii) the activity of one or more of the transcription factors NF-κB and AP-1; 
 (iv) the expression of the proinflammatory cytokine IL-1β, 
 wherein the method comprises administering an effective amount of 5-adamantan-1-yl-N-(2,4-dihydroxybenzyl)-2,4-dimethoxybenzamide of Chemical Formula 1, a pharmaceutically acceptable salt thereof, a hydrate thereof or a solvate thereof to a subject in need thereof: 
 
       
         
           
           
               
               
           
         
       
     
     
       2. The method according to  claim 1 , wherein the 5-adamantan-1-yl-N-(2,4-dihydroxybenzyl)-2,4-dimethoxybenzamide of Chemical Formula 1, the pharmaceutically acceptable salt thereof, the hydrate thereof or the solvate thereof inhibits the production of one or more of NO and PGE2. 
     
     
       3. The method according to  claim 1 , wherein the 5-adamantan-1-yl-N-(2,4-dihydroxybenzyl)-2,4-dimethoxybenzamide of Chemical Formula 1, the pharmaceutically acceptable salt thereof, the hydrate thereof or the solvate thereof inhibits the expression of one or more of iNOS and COX-2. 
     
     
       4. The method according to  claim 1 , wherein the 5-adamantan-1-yl-N-(2,4-dihydroxybenzyl)-2,4-dimethoxybenzamide of Chemical Formula 1, the pharmaceutically acceptable salt thereof, the hydrate thereof or the solvate thereof inhibits the activity of one or more of the transcription factors NF-κB and AP-1. 
     
     
       5. The method according to  claim 1 , wherein the 5-adamantan-1-yl-N-(2,4-dihydroxybenzyl)-2,4-dimethoxybenzamide of Chemical Formula 1, the pharmaceutically acceptable salt thereof, the hydrate thereof or the solvate thereof inhibits the expression of the proinflammatory cytokine IL-1β. 
     
     
       6. The method according to  claim 1 , wherein the 5-adamantan-1-yl-N-(2,4-dihydroxybenzyl)-2,4-dimethoxybenzamide of Chemical Formula 1, the pharmaceutically acceptable salt thereof, the hydrate thereof or the solvate thereof is administered in a form of composition, and the amount of 5-adamantan-1-yl-N-(2,4-dihydroxybenzyl)-2,4-dimethoxybenzamide of Chemical Formula 1, the pharmaceutically acceptable salt thereof, the hydrate thereof or the solvate thereof is 0.01-20 wt % based on the total weight of the composition. 
     
     
       7. The method according to  claim 6 , wherein the composition is a cosmetic composition. 
     
     
       8. The method according to  claim 6 , wherein the composition is a food composition. 
     
     
       9. The method according to  claim 6 , wherein the composition is a pharmaceutical composition.